Key takeaways
Foundayo (orforglipron) and Mounjaro (tirzepatide) are both medications that can help with weight management, but they belong to different drug classes. Foundayo is a GLP-1 agonist, while Mounjaro is a GIP and GLP-1 agonist. Foundayo is FDA-approved for weight loss in adults who are obese or overweight with a weight-related condition, whereas Mounjaro is approved for managing Type 2 diabetes in people 10 years and older, with weight loss being an off-label use. Foundayo is taken orally once a day, while Mounjaro is injected under the skin once a week. Foundayo is available as a tablet, and Mounjaro comes in various injectable forms, including pens and vials. Common side effects for both include nausea and diarrhea, but Foundayo may also cause constipation and vomiting more frequently. Both medications have a risk of thyroid cancer and pancreatitis, and they can interact with other medications, especially those affecting blood sugar levels.
